Using nasal delivery of specific peptides to treat Alzheimer's disease
Official title: Intranasal delivery of VGF-derived peptides in a preclinical model of Alzheimer's disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-11103164 · Data updated 2026-11-12
This study is looking at whether a special treatment delivered through the nose can help improve thinking and memory in people with Alzheimer's by reducing harmful brain deposits.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 15, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $760,250 |
| NIH project number | 5R01AG084699-02 |
| Project ID | NIH-11103164 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with late-onset Alzheimer's disease who may benefit from innovative treatment approaches.
✕Less likely to help
Patients with early-onset Alzheimer's disease or those with other forms of dementia may not receive benefit from this research.
What this research studies
This research investigates the potential of delivering VGF-derived peptides through the nasal route to improve cognitive function in Alzheimer's disease. By focusing on a preclinical model, the study aims to understand how these peptides can reduce amyloid deposition and cognitive impairment associated with Alzheimer's. The approach involves optimizing the delivery method to ensure effective absorption into the brain, leveraging the unique properties of the peptides to activate specific receptors involved in neuroprotection and cognitive enhancement.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic options that significantly improve cognitive function and slow the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in using similar peptide-based approaches for neuroprotection in Alzheimer's models, indicating potential for success in this novel application.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Salton, Stephen R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Salton, Stephen R
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.